What is the share price of Aspira Pathlab & Diagnostics Ltd (ASPIRA) today?
The share price of ASPIRA as on 21st September 2026 is ₹120.75. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.What is the return on Aspira Pathlab & Diagnostics Ltd (ASPIRA) share?
The past returns of Aspira Pathlab & Diagnostics Ltd (ASPIRA) share are- Past 1 week: 27.11%
- Past 1 month: 34.09%
- Past 3 months: -1.02%
- Past 6 months: 115.28%
- Past 1 year: 88.58%
- Past 3 years: 240.72%
- Past 5 years: 58.36%
What are the peers or stocks similar to Aspira Pathlab & Diagnostics Ltd (ASPIRA)?
The peers or stocks similar to Aspira Pathlab & Diagnostics Ltd (ASPIRA) include:What is the market cap of Aspira Pathlab & Diagnostics Ltd (ASPIRA) share?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Aspira Pathlab & Diagnostics Ltd (ASPIRA) is ₹118.37 Cr as of 21st September 2026.What is the 52 week high and low of Aspira Pathlab & Diagnostics Ltd (ASPIRA) share?
The 52-week high of Aspira Pathlab & Diagnostics Ltd (ASPIRA) is ₹135.88 and the 52-week low is ₹49.What is the PE and PB ratio of Aspira Pathlab & Diagnostics Ltd (ASPIRA) stock?
The P/E (price-to-earnings) ratio of Aspira Pathlab & Diagnostics Ltd (ASPIRA) is 2367.39. The P/B (price-to-book) ratio is 8.85.Which sector does Aspira Pathlab & Diagnostics Ltd (ASPIRA) belong to?
Aspira Pathlab & Diagnostics Ltd (ASPIRA) belongs to the Health Care sector & Hospitals & Diagnostic Centres sub-sector.How to buy Aspira Pathlab & Diagnostics Ltd (ASPIRA) shares?
You can directly buy Aspira Pathlab & Diagnostics Ltd (ASPIRA) shares on Tickertape. Simply sign up, connect your demat account and place your order.
Aspira Pathlab & Diagnostics Ltd
ASPIRA Share Price
BSE₹120.755.00% (+5.75)
High
—
—
Low
—
—
Returns
—
—
1D
1W
1M
1Y
5Y
Max
SIP
1D
1W
1M
1Y
5Y
Max
SIP
ASPIRA Stock Scorecard
Performance
AvgPrice return has been average, nothing exciting
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
HighShowing good signs of profitability & efficiency
Entry point
BadThe stock is in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
ASPIRA Performance & Key Metrics
ASPIRA Performance & Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| -251.85 | 8.85 | — |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 47.20 | 5.92 | 0.48% |
ASPIRA Analyst Ratings & Forecast
—
Analyst Ratings data is currently unavailable for this stockPrice Upside
Earnings Growth
Rev. Growth
ASPIRA Company Profile
Aspira Pathlab & Diagnostics Limited is an India-based company engaged in diagnostic centre and laboratories related business. The Company operates Pathology labs and diagnostics centers across India.
APOLLOHOSP
PE Ratio
66.23
66.23
1Y Return
15.26%
15.26%
Buy Reco %
86.67
86.67
MAXHEALTH
PE Ratio
70.80
70.80
1Y Return
8.84%
8.84%
Buy Reco %
83.33
83.33
MANIPALHOS
PE Ratio
108.93
108.93
1Y Return
12.16%
12.16%
Buy Reco %
62.50
62.50
FORTIS
PE Ratio
64.21
64.21
1Y Return
7.29%
7.29%
Buy Reco %
90.00
90.00
PE Ratio
169.57
169.57
1Y Return
16.45%
16.45%
Buy Reco %
90.91
90.91
ASPIRA Forecast
ASPIRA Forecasts
Forecast data is currently unavailable
Forecast data is currently unavailable
Price
Price Upside
Revenue
Revenue Growth
Earnings
Earnings Per Share
ASPIRA
ASPIRA
Income
Balance Sheet
Cash Flow
Quarterly Normal View
ASPIRA Income Statement
ASPIRA Income Statement
Quarterly Normal View
| Quarter | mar 2024 | jun 2024 | sep 2024 | dec 2024 | mar 2025 | jun 2025 | sep 2025 | dec 2025 | mar 2026 | jun 2026 | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 3.89 | 4.73 | 6.25 | 5.50 | 5.91 | 5.36 | 8.23 | 5.25 | 6.66 | 6.29 | ||||||||||
Operating & Other expenses | 3.94 | 4.29 | 4.82 | 4.64 | 4.72 | 4.43 | 5.90 | 6.33 | 6.86 | 5.83 | ||||||||||
EBITDA | -0.05 | 0.44 | 1.43 | 0.86 | 1.19 | 0.93 | 2.33 | -1.08 | -0.20 | 0.46 | ||||||||||
| Depreciation/Amortization | 0.38 | 0.38 | 0.36 | 0.39 | 0.37 | 0.37 | 0.40 | 0.38 | 0.40 | 0.41 | ||||||||||
| PBIT | -0.43 | 0.06 | 1.07 | 0.47 | 0.82 | 0.56 | 1.93 | -1.46 | -0.60 | 0.05 | ||||||||||
| Interest & Other Items | 0.08 | 0.08 | 0.08 | 0.09 | 0.09 | 0.09 | 0.10 | 0.10 | 0.10 | 0.09 | ||||||||||
| PBT | -0.51 | -0.02 | 0.99 | 0.38 | 0.73 | 0.47 | 1.83 | -1.56 | -0.70 | -0.04 | ||||||||||
| Taxes & Other Items | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||||||
| Net Income | -0.51 | -0.02 | 0.99 | 0.38 | 0.73 | 0.47 | 1.83 | -1.56 | -0.70 | -0.04 | ||||||||||
| EPS | -0.49 | -0.02 | 0.96 | 0.37 | 0.70 | 0.46 | 1.78 | -1.52 | -0.67 | -0.04 |
ASPIRA Company Updates
ASPIRA Stock Peers
ASPIRA Past Performance & Peer Comparison
ASPIRA Past Performance & Peer Comparison
Comparing 3 stocks from
Health CareHospitals & Diagnostic Centres
Compare valuation on Screener
Health CareHospitals & Diagnostic Centres
Valuation
Technical
Forecast
Compare valuation on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| Aspira Pathlab & Diagnostics Ltd | 2,367.39 | 8.85 | — |
| Apollo Hospitals Enterprise Limited | 66.23 | 12.89 | 0.22% |
| Max Healthcare Institute Limited | 70.80 | 9.50 | 0.19% |
| Manipal Health Enterprises Limited | 108.93 | 11.05 | — |
ASPIRA Stock Price Comparison
Compare ASPIRA with any stock or ETFCompare ASPIRA with any stock or ETF
ASPIRA
ASPIRA Holdings
ASPIRA Shareholdings
ASPIRA Promoter Holdings Trend
ASPIRA Promoter Holdings Trend
Increased Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook
In last 6 months, promoter holding in the company has increased by 28.19%
Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better
Pledged promoter holdings is insignificant
ASPIRA Institutional Holdings Trend
ASPIRA Institutional Holdings Trend
Decreased Total Retail Holding
Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.
In last 3 months, retail holding in the company has decreased by 1.25%
Foreign Institutional Holding
Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock
In last 3 months, foreign institutional holding of the company has almost stayed constant
ASPIRA Shareholding Pattern
ASPIRA Shareholding Pattern
ASPIRA Shareholding History
ASPIRA Shareholding History
Foreign Institutions
smallcases containing ASPIRA stock
smallcases containing ASPIRA stock
Looks like this stock is not in any smallcase yet.
ASPIRA Events
ASPIRA Events
ASPIRA Dividend Trend
No Dividends
Dividends are the portion of earnings that a company distributes to all its shareholders every year
ASPIRA has not given any dividends in last 5 years
Dividends
Corp. Actions
Announcements
Legal Orders
Dividends
ASPIRA Dividend Trend
No Dividends
Dividends are the portion of earnings that a company distributes to all its shareholders every year
ASPIRA has not given any dividends in last 5 years
ASPIRA Dividends
ASPIRA Dividends
Hmm, looks like data is unavailable here. Please come back after some timeASPIRA Stock News & Opinions
ASPIRA Stock News & Opinions
Articles & Videos
Spotlight
Spotlight
Aspira Pathlab plans Rs 65 crore rights issue to eligible shareholdersAspira Pathlab & Diagnostics Limited plans to raise up to Rs 65,00,00,000 through a rights issue to eligible equity shareholders, potentially offering equity or convertible instruments, subject to shareholder and regulatory approvals, with the issue price, entitlement ratio, and record date to be determined later. The board has also constituted a Right Issue Committee, comprised of Mr. Nikunj Velji Mange (Chairman), Mr. Vaibhav Odhekar, Mrs. Kiran Raghavendra awasthi, and Mr. Balkrishna Subhash Talawadekar, to finalize the terms and conditions of the rights offering.
1 week agoCapital Market - Live
Corporate
Corporate
Aspira Pathlab may raise funds through equity shares or warrants, filings showAspira Pathlab & Diagnostics Limited will seek shareholder and statutory approvals to raise funds through the issuance of instruments including equity shares or warrants convertible into equity shares via preferential issue, private placements, rights issue, or other permitted methods, the company said in a filing to the BSE Limited on September 7, 2026.
2 weeks agoCapital Market - Live
Corporate
Corporate
Aspira Pathlab’s book closure set for September 19-25, 2026, for annual meetingAspira Pathlab & Diagnostics Limited has informed the BSE Limited that its book closure will be from September 19, 2026, to September 25, 2026, for the purpose of the 53rd Annual General Meeting scheduled to be held on September 25, 2026, at 2:00 P.M. via video conferencing or other audio visual means. The e-voting period will be from 9:00 A.M. (IST) on September 22, 2026, to 5:00 P.M. (IST) on September 24, 2026, with a cut-off date of September 18, 2026.
2 weeks agoCapital Market - Live
Corporate
Corporate
Aspira Pathlab to consider financial results and potential fundraising at board meetingAspira Pathlab & Diagnostics Limited will hold a board meeting on August 12, 2026, to consider and approve the unaudited financial results for the first quarter ended June 30, 2026, and to evaluate a proposal for raising funds through instruments including equity shares or warrants convertible into equity shares, via preferential issue, private placements, rights issue, or other permitted methods.
1 month agoCapital Market - Live
Earnings
Earnings
Aspira Pathlab & Diagnostics reports standalone net loss of Rs 0.69 crore in the March 2026 quarterNet loss of Aspira Pathlab & Diagnostics reported to Rs 0.69 crore in the quarter ended March 2026 as against net profit of Rs 0.72 crore during the previous quarter ended March 2025. Sales rose 12.80% to Rs 6.52 crore in the quarter ended March 2026 as against Rs 5.78 crore during the previous quarter ended March 2025. For the full year,net profit declined 97.58% to Rs 0.05 crore in the year ended March 2026 as against Rs 2.07 crore during the previous year ended March 2025. Sales rose 13.55% to Rs 24.98 crore in the year ended March 2026 as against Rs 22.00 crore during the previous year ended March 2025. ParticularsQuarter EndedYear EndedMar. 2026Mar. 2025% Var.Mar. 2026Mar. 2025% Var. Sales6.525.78 13 24.9822.00 14 OPM %-5.0618.17 -5.8416.00 - PBDT-0.291.09 PL 1.593.56 -55 PBT-0.690.72 PL 0.052.07 -98 NP-0.690.72 PL 0.052.07 -98 Powered by Capital Market - Live
3 months agoCapital Market - Live
Corporate
Corporate
Aspira Pathlab & Diagnostics to announce Quarterly ResultAspira Pathlab & Diagnostics will hold a meeting of the Board of Directors of the Company on 23 May 2026.
4 months agoCapital Market - Live
Earnings
Earnings
Aspira Pathlab & Diagnostics reports standalone net loss of Rs 1.56 crore in the December 2025 quarterNet loss of Aspira Pathlab & Diagnostics reported to Rs 1.56 crore in the quarter ended December 2025 as against net profit of Rs 0.38 crore during the previous quarter ended December 2024. Sales declined 5.36% to Rs 5.12 crore in the quarter ended December 2025 as against Rs 5.41 crore during the previous quarter ended December 2024. ParticularsQuarter EndedDec. 2025Dec. 2024% Var. Sales5.125.41 -5 OPM %-23.6314.23 - PBDT-1.180.77 PL PBT-1.560.38 PL NP-1.560.38 PL Powered by Capital Market - Live
7 months agoCapital Market - Live
Corporate
Corporate
Aspira Pathlab & Diagnostics to declare Quarterly ResultsAspira Pathlab & Diagnostics will hold a meeting of the Board of Directors of the Company on 10 February 2026.Powered by Capital Market - Live
7 months agoCapital Market - Live
Earnings
Earnings
Aspira Pathlab & Diagnostics standalone net profit rises 85.86% in the September 2025 quarterNet profit of Aspira Pathlab & Diagnostics rose 85.86% to Rs 1.84 crore in the quarter ended September 2025 as against Rs 0.99 crore during the previous quarter ended September 2024. Sales rose 30.91% to Rs 8.09 crore in the quarter ended September 2025 as against Rs 6.18 crore during the previous quarter ended September 2024. ParticularsQuarter EndedSep. 2025Sep. 2024% Var. Sales8.096.18 31 OPM %27.1921.84 - PBDT2.241.35 66 PBT1.840.99 86 NP1.840.99 86 Powered by Capital Market - Live
10 months agoCapital Market - Live
Corporate
Corporate
Aspira Pathlab & Diagnostics to announce Quarterly ResultAspira Pathlab & Diagnostics will hold a meeting of the Board of Directors of the Company on 12 November 2025.Powered by Capital Market - Live
10 months agoCapital Market - Live
Over the last 5 years, revenue has grown at a yearly rate of 10.6%, vs industry avg of 18.03%
Over the last 5 years, market share decreased from 0.04% to 0.02%
Over the last 5 years, net income has grown at a yearly rate of -48.57%, vs industry avg of 62.59%